Bristol-Myers Squibb ( BMY) said Wednesday it plans to sell its U.S. and Canadian consumer medications business, including the pain reliever Excedrin. The company will contact prospective buyers "over the coming weeks."

Bristol-Myers Squibb, however, said it would retain its consumer medicines operations in Asia, Latin America, Africa and Europe because these units "remain an important part of the company's pharmaceutical business within each region."

The U.S. and Canadian businesses, which include Excedrin and three other nonprescription products, produced $240 million in sales in 2003. Total corporate revenue was $20.7 billion in 2003.

Last month, the company signed a definitive agreement to sell its Oncology Therapeutics Network unit to One Equity Partners. The deal is expected to be completed in the first quarter, pending regulatory approval. The company didn't announce a price.

OTN distributes drugs to cancer specialists. In 2003, it produced revenue of $2.2 billion, and earnings before minority interest and income taxes of $14 million.

Bristol-Myers Squibb's stock was down 5 cents to $24.55 on Wednesday.